Tularemia in the US: a rare disease that's not going away
Every year, about 200 Americans get tularemia. Most recover, but some die. The US tularemia market report by MRFR shows that serological testing is the largest diagnosis method, but molecular diagnostics is the fastest‑growing. The market is $30.66 million and will hit $51.13 million by 2035, growing at 4.76% CAGR. Why the steady growth? Because the CDC tracks tularemia, and...
0 Comentários 0 Compartilhamentos 20 Visualizações 0 Anterior